Aptinyx trades as part of the biotechnology industry and healthcare sector. The company CEO is Norbert G. Riedel. Aptinyx Inc is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel, proprietary, synthetic small molecules for the treatment of brain and nervous system disorders.



Previous Intraday Performance:

The APTX shares had a previous change of 0.78% which opened at 3.88 and closed at 3.89. It moved to an intraday high of 3.97 and a low of 3.77.

SeekingAlpha:  STM, OPTT among premarket gainers

Historical Performance:

Over the last five trading days, APTX shares returned -5.35% and in the past 30 trading days it returned -27.83%. Over three months, it changed -78.18%. In one year it has changed -80.74% and within that year its 52-week high was 32.25 and its 52-week low was 3.70. APTX stock is 5.14% above its 52 Week Low.

Our calculations result in a 200 day moving average of 17.85 and a 50 day moving average of 4.78. Right now, APTX stock is trading -78.21% below its 200 day moving average and may not be a great opportunity to buy as it may continue to trend down.

SeekingAlpha:  Aptinyx up 13% premarket on NYX-458 data in Parkinson’s

Liquidity:

The company has a market cap of $130.6m with 33.6m shares outstanding and a float of 32.2m shares. Trading volume was 331,945 shares and has experienced an average volume of 529,300 shares. Our calculation, using the current average volume and close price, leads me to believe that the liquidity is bad, highly speculative and an investor may want to avoid this stock.

Earnings:

The last annual reported EPS for Aptinyx was -2.87 which ended on 31st of December 2018. Based on 1 analyst estimate, the estimated EPS for the next quarter is -0.54.

The next earnings report will be: 04-22-2019

EPS growth is an important number as it indicates the future prospects of Aptinyx; it is typically displayed as a percentage and called the EPS growth rate, which at this time is hard to estimate, but revenue growth has been -66.00% over the last twelve months.

Indicators Also to Watch:

Based on the latest filings, there is 4.20% of insider ownership and 73.00% of institutional ownership.



I calculated the beta to be -0.89

SeekingAlpha:  Aptinyx up 13% premarket on NYX-458 data in Parkinson’s

Fundamental Numbers:

Based on last reported financials, the company’s return on equity is -97.23%, return on assets is -42.13%, price-to-sales is 31.52 and price-to-book is 0.87.

Company Score Card:

Results are out of six:
 1  : Growth Expectations Result
 6  : Financial Safety Result
 0  : Past Performance Result
 1  : Valuation Result
 0  : Dividend Safety Result
 2  : Overall Result

Related Tags: , , ,

Jake McWilliams
I am an independent trader, analyst and algorithmic trading expert, having worked both for the sell side (brokerage) and the buy side (fund administration). I have been trading professionally for about 20 years. I trade stocks and forex and I play both long and short positions in underlying asset or through options. I have experience with discretionary and fully automated systems (Metatrader and Quantshare).

LEAVE A REPLY

Please enter your comment!
Please enter your name here